A proposed Chinese export-control update could limit foreign acquisitions of biotech platforms, while the FTC seeks information from OpenAI and Anthropic in a separate consumer-protection inquiry.
Two recent developments involving China’s biotech sector and the Federal Trade Commission’s scrutiny of artificial-intelligence companies point to different forms of oversight over valuable technology. Neither, on the available information, amounts to a conventional U.S. merger challenge or a finding that a company has violated antitrust law. But both raise questions about who controls technology, how it can be transferred and what protections apply when powerful firms shape markets and services.
China’s proposed export-control update would ban foreign acquisitions of proprietary platforms in cell and gene therapy, siRNA and pathogen gain-of-function research, according to Fierce Biotech. It would also require approval for overseas transfers of proprietary technologies used to identify and verify targets. The draft list is open for public comment through November 15, 2026.
The proposal appears to distinguish ownership changes from other commercial arrangements. According to China’s Ministry of Commerce, out-licensing and outsourced research or manufacturing using the relevant know-how would still be permitted. Out-licensing of target-identification and verification technologies would generally be approved, Fierce Biotech reported.
That distinction matters for biotech companies seeking overseas partners. A ban on acquisition does not necessarily shut off access to a technology: licensing or contract work may remain possible. But approval requirements and limits on ownership could change how companies structure deals and who can exercise long-term control over a platform. The available reporting does not establish how the rules would be applied in individual cases or what effect they would have on prices, research or competition.
Fierce Biotech also reported that Chinese authorities are responding to a growing volume of foreign interest in domestic biotech assets. The figures cited in the supplied material are unverified, however, and should not be used to quantify that activity. PharmCube data cited by the publication reportedly showed that only a minority of cross-border biopharma out-licensing deals involved transfers of ownership, but the underlying totals were not verified in the material available here.
In the United States, the FTC sent civil investigative demands to OpenAI and Anthropic on October 14, seeking records on security incidents, safeguards, marketing materials and privacy policies, Axios reported. OpenAI said it would “engage constructively with the FTC.” The agency is examining possible consumer-protection violations connected to alleged unsafe, deceptive or aggressive model behavior, according to Axios.
That inquiry should not be mistaken for an antitrust case. The reported focus is whether companies’ conduct and disclosures may have harmed consumers—not whether a merger should be blocked or a dominant firm has unlawfully restrained competition. The FTC’s request for information is an investigative step, not a determination of wrongdoing. The supplied reporting also says the agency plans to compel testimony from leading AI executives and may later send demands to third-party AI organizations.
The distinction is important as AI companies compete for users, customers and influence over services. Consumer protection can address risks that competition policy may not; antitrust enforcement, in turn, examines market power and the ability of firms to shut out rivals. The current information does not establish that OpenAI or Anthropic holds monopoly power, or that the FTC has opened a competition case against either company.
The available headlines offer no basis for a broader verdict on enforcement. One concerns China’s proposed restrictions on foreign ownership and technology transfers; the other is a U.S. inquiry into AI safety and consumer protection. The Cleveland case involving Dojuan Nettles and Dionte Davis, also among recent headlines, is unrelated to antitrust and provides no evidence on corporate power. More detail will be needed to assess the practical effects of either policy development on rivals, customers or research.
Greg Sanders serves as the Senior Correspondent for Corporate Power and Antitrust at Just Right News, where he brings a principled, conservative perspective to the complex intersection of big business, government regulation, and the American consumer. With a career dedicated to investigative depth and economic clarity, Greg has become a leading voice in examining how the consolidation of industry power impacts the foundational values of the free market and individual liberty.
Raised in Denver, Colorado, Greg’s reporting is deeply informed by the Western spirit of independence and a healthy skepticism of centralized authority. Growing up in the shadows of the Rockies, he witnessed firsthand the importance of local entrepreneurship and the vital role that small-medium enterprises play in sustaining vibrant communities. This upbringing instilled in him a belief that the American Dream is best preserved when the playing field remains level and when competition—rather than backroom deals between corporate lobbyists and federal regulators—dictates success. For Greg, the rugged individualism of his home state serves as a constant reminder that the economy should serve the people, not the other way around.
Now based in Chicago, Illinois, Greg operates from the heart of the nation’s industrial and financial crossroads. His location in the Midwest provides him with a unique vantage point to observe the real-world consequences of corporate overreach. From the boardrooms of the Loop to the manufacturing hubs that define the region, he tracks the movement of capital and the shifting tides of market influence. Chicago’s history as a center of trade and labor offers a rich backdrop for his work, allowing him to bridge the gap between high-level economic theory and the lived experiences of hardworking Americans who feel the squeeze of monopolistic practices.
At Just Right News, Greg’s beat focuses on the “new monopolies” and the rise of “woke” corporate culture. He argues that when corporations become too large, they often abandon their fiduciary duties to shareholders in favor of social engineering and political posturing. His reporting seeks to hold these “Titans” accountable, ensuring that the power of the purse is not used to silence dissent or bypass the democratic process. He is a firm advocate for the idea that true conservatism requires a vigilant defense of competition, preventing any single entity—public or private—from exerting undue control over the lives of citizens.
This mission is most clearly seen in his acclaimed feature series, “The Titans and the Toll.” In this ongoing project, Greg explores the human cost of market consolidation, from the erosion of consumer choice to the decline of local economies. Through rigorous analysis and boots-on-the-ground reporting, he documents how the concentration of power in sectors like tech, agriculture, and finance creates a “toll” paid by the average family.
Greg Sanders remains committed to the idea that a transparent, competitive market is the greatest engine for prosperity ever devised. Through his work at Just Right News, he continues to provide the essential oversight necessary to protect that engine from the encroaching influence of corporate giants and the bureaucratic structures that enable them.